Big Pharma prunes R&D as times get tough

GlaxoSmithKline pland to cut up to 850 jobs in R&D, while Pfizer revealed its decision to drop efforts to develop medicines for heart disease

Realty cos on costcutting spree to fight tough times

CEOs likely to get least salary hikes

Pharma firms betting big on nutraceuticals

Realty: Tough to buy, tougher to rent

Tough to say when Taj operation gets over: Indian Hotels

Workers of bangle industry face tough time

Why did Devkumar Vaidya sell out Zandu Pharma?

This entry was posted on Tuesday, October 7th, 2008 at 9:14 pm and is filed under Pharma. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Indian Stock Market

Big Pharma prunes R&D as times get tough

Leave a Reply

Categories

Archives

Feed

Links

Subscribe by E-Mail :

Recent Posts

Recent Comments

Indian Stock Market News